Lee H S, Rajagopalan M S, Chien D, Cordell R, Perkins H A, Vyas G N
Transfusion. 1987 Jan-Feb;27(1):103-6. doi: 10.1046/j.1537-2995.1987.27187121450.x.
Hepatitis B core antibody (anti-HBc) is currently tested by a competitive inhibition enzyme immunoassay (EIA), using recombinant DNA-produced core antigen. We have used the anti-HBc assay in routine screening of voluntary blood donors in San Francisco. The detection rate of anti-HBc was 2.08 percent. The specificity of the antibody test was established by an absorption method using purified HBc antigen (HBcAg) produced by recombinant DNA technology and covalently coupled to Sepharose 4B. Bovine serum albumin was used in the preparation of a control conjugate. The absorption test demonstrated that out of 98 anti-HBc-positive specimens, 97 could be specifically neutralized. Only one specimen was indeterminate. The absorption test was particularly useful in confirming the specificity of EIA in eight specimens inconsistently positive for anti-HBc. We conclude that the current EIA for anti-HBc is highly specific and we are of the opinion that it could be used as a rational basis for donor deferral since it gives evidence of active or previous HBV infection.
乙肝核心抗体（抗-HBc）目前通过竞争性抑制酶免疫测定法（EIA）检测，使用重组DNA生产的核心抗原。我们已将抗-HBc检测用于旧金山自愿献血者的常规筛查。抗-HBc的检出率为2.08%。抗体检测的特异性通过吸收法确定，该方法使用重组DNA技术生产并共价偶联到琼脂糖4B上的纯化乙肝核心抗原（HBcAg）。牛血清白蛋白用于制备对照偶联物。吸收试验表明，在98份抗-HBc阳性标本中，97份可被特异性中和。只有一份标本结果不确定。吸收试验在确认8份抗-HBc结果不一致呈阳性的标本中EIA的特异性方面特别有用。我们得出结论，目前的抗-HBc EIA具有高度特异性，并且我们认为它可以作为献血者延期的合理依据，因为它能提供现症或既往HBV感染的证据。
